Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
OSGEPL1 antisense RNA 1 (OSGEPL1-AS1)
- Target
- OSGEPL1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other (non-protein coding transcript)
01
Overview
OSGEPL1 antisense RNA 1 (OSGEPL1-AS1) is a long non-coding antisense transcript from the OSGEPL1 gene locus. Antisense RNAs generally function to regulate gene expression through a variety of mechanisms, including modulation of their corresponding sense mRNAs or interference with transcription, splicing, or translation[5]. While the OSGEPL1 protein product itself has been implicated as an oncogenic driver in cancer, particularly liver cancer and high-grade ovarian cancer[4], the specific biological significance of OSGEPL1-AS1 remains uncharacterized in published literature. As with other long non-coding antisense RNAs, OSGEPL1-AS1 may exert regulatory effects on the OSGEPL1 gene, but there is currently no evidence that it is a direct therapeutic target or is associated with disease as a biomarker, nor are drugs known to interact with it[2][5].
- Other names
- OSGEPL1-AS1OSGEPL1 antisense RNA 1 (non-protein coding)OSGEPL1 antisense RNA 1
02
Biological functions
Regulation of gene expression (esp. via antisense mechanisms)Potential modulation of OSGEPL1 expression (by antisense interaction)Epigenetic or transcriptional regulation (inferred from general lncRNA and antisense RNA biology)
03
Disease associations
Other (no direct disease association documented for OSGEPL1-AS1; primary research focuses on the protein-coding OSGEPL1 gene, which is implicated in cancer such as hepatocellular carcinoma, but not directly on the antisense RNA)
Beyond the preview
Go deeper on OSGEPL1 antisense RNA 1 (OSGEPL1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSGEPL1 antisense RNA 1 (OSGEPL1-AS1).